Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

CONCLUSION: Atezolizumab represents a cost-effective therapeutic option in Canada for the treatment of patients with advanced NSCLC who progress after first-line platinum doublet chemotherapy.
PMID: 30836031 [PubMed - as supplied by publisher]

Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research